← Back to Clinical Trials
Recruiting NCT05880173

NCT05880173 SCREaning of Advanced Liver Fibrosis Using Non-Invasive Tests in General Population

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05880173
Status Recruiting
Phase
Sponsor University Hospital, Angers
Condition Screening
Study Type INTERVENTIONAL
Enrollment 502 participants
Start Date 2023-10-20
Primary Completion 2027-03

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 75 Years
Study Type INTERVENTIONAL
Interventions
FIB4

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 502 participants in total. It began in 2023-10-20 with a primary completion date of 2027-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The main objective of the study is to evaluate the pertinence of initiating screening for advanced hepatic fibrosis after a FIB4 result \> 2.67 automatically calculated in the local laboratory and followed by a specialized hepatic evaluation.

Eligibility Criteria

Inclusion Criteria: * Age between 18 and 70 years * Blood sample taken at a medical testing laboratory selected for the study. * Biology without high risk of false positive result for FIB4 (AST and ALT ≤ 300 IU/l ; Platelets ≥ 50 G/l and \< 500 G/l.) * FIB4 \> 2.67 after automatic calculation in the medical laboratory less than 3 months old * Signature of informed consent to participate in the study Exclusion Criteria: * Ongoing specialized follow-up for a chronic liver disease * Difficulty understanding the French language * Pregnant women, breastfeeding or parturient women * Persons suspended from liberty by judicial or administrative decision * Persons under legal protection * Persons unable to express their consent * Non affiliation to a social security system

Contact & Investigator

Central Contact

Clémence CANIVET, MD, PHD

✉ clemence.canivet@chu-angers.fr

📞 (0)241353142

Frequently Asked Questions

Who can join the NCT05880173 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Screening. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05880173 currently recruiting?

Yes, NCT05880173 is actively recruiting participants. Contact the research team at clemence.canivet@chu-angers.fr for enrollment information.

Where is the NCT05880173 trial being conducted?

This trial is being conducted at Angers, France, Angers, France, Grenoble, France, Lens, France and 2 additional locations.

Who is sponsoring the NCT05880173 clinical trial?

NCT05880173 is sponsored by University Hospital, Angers. The trial plans to enroll 502 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology